What is PreciseDx?
PreciseDx positions itself as a unique entity in the cancer risk stratification landscape, offering patient-specific risk information derived from the analysis of morphology features. This approach aims to facilitate more precise and personalized treatment strategies, ultimately leading to improved patient outcomes. The company's focus on detailed morphological analysis suggests a deep commitment to advancing diagnostic precision in oncology.
How much funding has PreciseDx raised?
PreciseDx has raised a total of $42.5M across 3 funding rounds:
Series A
$10.8M
Series B
$20.7M
Other Financing Round
$11M
Series A (2022): $10.8M with participation from Mount Sinai Health System, Agile Technologies, and Merck GHI
Series B (2024): $20.7M led by Eventide Asset Management, Quest Diagnostics, and Labcorp
Other Financing Round (2025): $11M supported by Philip Ventures, GenHenn Capital, Merck & Co, Eventide Asset Management, Labcorp, and Quest Diagnostics Inc
Key Investors in PreciseDx
Eventide Asset Management
Eventide Asset Management is an investment firm focused on helping investors pursue integrity, impact, and outperformance, with a diverse range of funds including those focused on healthcare and technology.
Quest Diagnostics
Quest Diagnostics is a leading provider of diagnostic insights, offering a broad test menu and pioneering innovative tests, particularly in cancer diagnostics and anatomic pathology.
Labcorp
Labcorp Holdings Inc. provides vital laboratory services and diagnostic information to aid in decision-making for healthcare professionals and patients, with a strong focus on diagnostics and biopharma services.
What's next for PreciseDx?
The recent major enterprise-level funding, characterized as a Series B round, indicates that PreciseDx is likely entering a significant scaling phase. This capital infusion is expected to fuel further research and development, expand market reach, and potentially enhance its technological infrastructure. The strategic nature of the investment suggests a strong alignment with the company's long-term vision and growth trajectory, positioning it for accelerated development in the competitive healthcare technology sector.
See full PreciseDx company page
